Matinas Biopharma Holdings Inc (MTNB) Quote

maybe tomorrow

Hit .91 premarket...Over $1 today?

Go go go.

Got my eyes on MTNB. Took a starter at 0.57

Wow, I forgot all about this pretty baby! Thank you for waking me up. Papi always takes care of his friends.🤩😇

Papi wants $1 at .85 cents 5m floater 

Hope MTNB will be bought
——————
About MAT2203?
Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.

MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival.

MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.

The company could sell this MAT2203.
Let's hope for the best. Perhaps MTNB can be bought by some larger pharmaceutical company.
They are a good group of research scientists, biologists. Something boiling, going on. Wait and see.

About MAT2203
Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.

About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.

For more information, please visit www.matinasbiopharma.com.

--Maxim Downgrades Matinas BioPharma to Hold From Buy
12:52 PM ET 10/31/24 | MT Newswires
--Maxim Downgrades Matinas BioPharma to Hold From Buy

I will hang on for a short while. HOLD, not Sell.
Expect other large company will take over MTNB

12:52 PM EDT, 10/31/2024 (MT Newswires) --

Price: 0.60, Change: -1.33, Percent Change: -68.96

Matinas BioPharma (NYSE American: MTNB) announces the termination of negotiations for global rights to MAT2203, its oral formulation of amphotericin B. In response, the company has implemented an immediate 80% workforce reduction, eliminating 15 positions including three senior management members. The company has ceased all product development activities to conserve cash. The Board plans to retain an advisor to explore potential sale of MAT2203, their Phase 3-ready antifungal drug candidate, and will evaluate other alternatives including possible company winddown and dissolution.

What's going on with MTNB today!

Oh no, so unfortunate, Reverse Split, devalue our hard- earned monies

So they are cutting the AS in half yet doing a 50 times to 1 Reverse Split ------ seems like commons are being screwed 90 times more than the AS reduction.

Matina has a great future. Buy and hold patiently.

Good news for MTNB
"We project that the market for MAT2203 in the treatment of invasive aspergillosis in patients with limited treatment options could reach peak sales in the U.S. alone of over $400 million annually..."

Added more to the stash on this good news

glad i got out pre mkt. their fins came out and didnt sound good, but it was fun while it lasted.

back in on the dip.

looking good in post hours.

here we go!

in at .2772. i like how this one moves (in the past) and how its quietly inching up.

MTNB onto $.15 or .16 as they dump more stock.

mb

Too much selling for days means we are going lower. RS expected which will also damage the stock.



MTNB

mb

It has a BUY rating & Med value $ 1.65 - $ 3.00 PPS.

Best to keep it under radar until it is trading solidly in the $ .35-.40s.

They will find it eventually.

mb

Bought .25 & .26 > MTNB is a great $$$$$ opportunity!

The MTNB game is all about recognition in the Bio world. The stock will be rising to find a proper value. However, if they provide any more substantial news, this may be running quickly as many accumulate under $.30

mb

everybody uses the RS trying to get the PPS to drop we already know that's not going to happen.

OK Let’s see if they short!
more tomorrow; Or do a reverse split?

Reset for next run... on sale

MTNB has a Target mid price at $1.65 Average Recommendation BUY

I think we are just getting starting

Looks like this is done. But at least I sold my .30s for a profit

Biotech Catches Massive Premarket Bid
By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, October 11, 2023

A New Jersey-based biotech company is catching a serious premarket bid this morning following a press release detailing the company’s announcement that they completed clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei, a fluconazole inherited resistant fungal pathogen, following treatment with the company’s MAT2203.

Traders immediately got excited about this news, as shares of Matinas Biopharma Holdings Inc. (NYSE American: MTNB) are currently bid up at $0.2693/share (+73.74% implied open for sellers) at the time of writing. This should be an exciting session for this micro cap!

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Copyright © 2023 AllPennyStocks.com. All rights reserved.

About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.

Matinas’ lead which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV AMB in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.

In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as RNAi, antisense oligonucleotides, and vaccines. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.

Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact

LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

CONFERENCE TODAY Oct.12 and THURSDAY Oct. 19 next week

September 28 2023 - 07:00AM
GlobeNewswire Inc.
Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:

Dawson James Small Cap Growth Conference being held Thursday, October 12 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. The presentation is scheduled for 3:30 p.m. Eastern time.

The ThinkEquity Conference being held Thursday, October 19 at the Mandarin Oriental Hotel in New York City.
The presentation is scheduled for 11:00 a.m. Eastern time.

A webcast of the presentation at the Dawson James Small Cap Growth Conference will be available live on the IR Calendar page of the Investors section of the company’s website. The webcast will be archived for 90 days. Institutional investors interested in arranging a meeting with Matinas BioPharma management, please contact Jody Cain at LHA investor relations at jcain@lhai.com.

Try to HOLD. This is a good stock.
Take a look: who are the financial institution
large shareholders of MTNB?
Largest shareholders include
Vanguard Group Inc, VTSMX
Vanguard Total Stock Market Index Fund Investor Shares,
Sargent Investment Group, LLC, BlackRock Inc.,
VEXMX - Vanguard Extended Market Index Fund Investor Shares,
Geode Capital Management, Llc,
Arkadios Wealth Advisors,
Neville Rodie & Shaw Inc,
FSMAX - Fidelity ...

2 CONFERENCES IN OCTOBER 2023

$MTNB - #DDAmanda Video Analysis

#DDAmanda Halloween Special: https://DDAmanda.com/SignUpHalloween164.php



Z

YEAH BIG move !
I was lucky to add 7000 shares at .14 ❤️😃👍
I WILL HOLD TILL OVER $3
A small and promising company
Best wishes everyone! Trust in MTNB !

Just hold .35. I need to squeeze at least 5% out of this geez. Haha.

HOLD THIS ONE ? CONFERENCE JUST STARTING ?

Huge conference starts today. > It's exciting to share the ongoing, consistent positive clinical impact of our broad-spectrum, fast-acting oral MAT2203, especially with a major infectious disease conference, IDWeek, kicking off today," said Theresa Matkovits, PhD, Chief Development Officer at Matinas. "We look forward to advancing MAT2203 into a Phase 3 registration trial to evaluate its potential in patients suffering from invasive aspergillosis who have limited or no treatment options. We believe that oral, effective, and safe MAT2203, if approved, would represent a dramatic improvement to current clinical standard of care and become the treatment of choice for patients and physicians battling invasive fungal infections. We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections."

wow why didn't I know about this one?

Profits

I have no more day trades left for the week unfortunately. My .30 buy from this morning will most likely have all rofut wiped out by 7 am when I can sell in the morning

I sold yesterday once it fell way under .15. Sucks. Bought a few shares for a gamble this morning but not near what I sold yesterday. Normal occurrence for me.

What a great $$$$$ opportunity!

MTNB

Boooyaaaa

Monster